Zobrazeno 1 - 10
of 182
pro vyhledávání: '"Daniel Addison"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Externí odkaz:
https://doaj.org/article/ccb72653a55d46348b4eb44b59d9c124
Autor:
Ikeoluwapo Kendra Bolakale-Rufai, Alexander Shinnerl, Shannon M. Knapp, Amber E. Johnson, Selma Mohammed, LaPrincess Brewer, Asad Torabi, Daniel Addison, Sula Mazimba, Khadijah Breathett
Publikováno v:
American Heart Journal Plus, Vol 39, Iss , Pp 100370- (2024)
Background: Transcatheter aortic valve replacement (TAVR) are not offered equitably to vulnerable population groups. Adequate levels of insurance may narrow gaps among patients with higher social vulnerability index (SVI). Among a national population
Externí odkaz:
https://doaj.org/article/d65623d3c1134495b311685932cf936a
Autor:
Ahmed Sayed, Malak Munir, Eric H Yang, Daniel Addison, Sarah Khan, Jiwon Kim, Syed Mahmood, Narendranath Epperla, Alexa Meara, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sneha Sharma, Stephanie Feldman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associa
Externí odkaz:
https://doaj.org/article/4daf6a6fa2be4e8dbd01f020034d0b6a
Autor:
Sherry-Ann Brown, Craig Beavers, Brenton Bauer, Richard K. Cheng, Generika Berman, Catherine H. Marshall, Avirup Guha, Prantesh Jain, Austin Steward, Jeanne M. DeCara, Iredia M. Olaye, Kathryn Hansen, Jim Logan, Carmen Bergom, Carri Glide-Hurst, Irving Loh, John Alan Gambril, James MacLeod, Ragasnehith Maddula, Peter J. McGranaghan, Akshee Batra, Courtney Campbell, Abdulaziz Hamid, Fatma Gunturkun, Robert Davis, John Jefferies, Michael Fradley, Katherine Albert, Anne Blaes, Indrajit Choudhuri, Arjun K. Ghosh, Thomas D. Ryan, Ogochukwu Ezeoke, Douglas J. Leedy, Wadsworth Williams, Sebastian Roman, Lorenz Lehmann, Abdullah Sarkar, Diego Sadler, Elizabeth Polter, Kathryn J. Ruddy, Neha Bansal, Eric Yang, Brijesh Patel, David Cho, Alison Bailey, Daniel Addison, Vijay Rao, Joshua E. Levenson, Dipti Itchhaporia, Karol Watson, Martha Gulati, Kim Williams, Donald Lloyd-Jones, Erin Michos, Julie Gralow, Hugo Martinez
Publikováno v:
American Heart Journal Plus, Vol 38, Iss , Pp 100354- (2024)
As cancer therapies increase in effectiveness and patients' life expectancies improve, balancing oncologic efficacy while reducing acute and long-term cardiovascular toxicities has become of paramount importance. To address this pressing need, the Ca
Externí odkaz:
https://doaj.org/article/8043007b5ee04ac89d1b9f4d2fd3cdc7
Autor:
Rebecca R. Carter, Aaron P. Chum, Reynaldo Sanchez, Avirup Guha, Amit K. Dey, Raquel Reinbolt, Lisa Kim, Prince Otchere, Oduro Oppong‐Nkrumah, William T. Abraham, Maryam Lustberg, Daniel Addison
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 297-305 (2023)
Abstract Background Contemporary therapies improve breast cancer (BC) outcomes. Yet, many of these therapies have been increasingly linked with serious cardiotoxicity, including reports of profound hypertension. Yet, the incidence, predictors, and im
Externí odkaz:
https://doaj.org/article/b98526d799604c008fd0092db7ca46e3
Autor:
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-11 (2022)
Abstract Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (nex
Externí odkaz:
https://doaj.org/article/d6745f39b574408fa6a4ea02615773a4
Autor:
Avirup Guha, Anubhav Jain, Ankita Aggarwal, Amit K. Dey, Sourbha Dani, Sarju Ganatra, Francis E. Marchlinski, Daniel Addison, Michael G. Fradley
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background The aim of this study is to assess the burden of AF-related hospitalizations inclusive of inflation-adjusted cost-of-care and length-of-stay (LOS) among cancer patients and the impact of direct current cardioversion (DCCV) on thes
Externí odkaz:
https://doaj.org/article/e753efc0c630434a85c1c7949515530d
Autor:
Malek Z O Hassan, Ahmed Tawakol, Ying Wang, Raza M Alvi, Magid Awadalla, Maeve Jones-O'Connor, Rula B Bakar, Dahlia Banerji, Adam Rokicki, Lili Zhang, Connor P Mulligan, Michael T Osborne, Azmaeen Zarif, Basma Hammad, Annie W Chan, Lori J Wirth, Erica T Warner, Roger K Pitman, Katrina A Armstrong, Daniel Addison, Tomas G Neilan
Publikováno v:
PLoS ONE, Vol 18, Iss 8, p e0279235 (2023)
ImportanceThe mechanisms underlying the association between chronic stress and higher mortality among individuals with cancer remain incompletely understood.ObjectiveTo test the hypotheses that among individuals with active head and neck cancer, that
Externí odkaz:
https://doaj.org/article/124443f4e6884192b4caaaaad8edda33
Autor:
Vineeth Sukrithan, Lisa Kim, Jennifer A. Sipos, Ashima Goyal, Ye Zhou, Daniel Addison, Manisha Shah, Bhavana Konda, Ajay Vallakati
Publikováno v:
Case Reports in Endocrinology, Vol 2023 (2023)
A subset of patients with differentiated thyroid carcinoma develop radioiodine refractory (RAIR) incurable disease, which typically has a poor prognosis. The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements
Externí odkaz:
https://doaj.org/article/4337e1f4ed4b4dcfab351e697d0c32a1
Autor:
Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu, Daniel Addison
Publikováno v:
Cardio-Oncology, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Background Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib may be associated wi
Externí odkaz:
https://doaj.org/article/b4306920ee594eb89324f714cb2457be